Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Value investing can be a powerful strategy for new investors. Learn key tips to enhance your investment skills and achieve better returns.
28,096 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Nvidia just increased holding in a high-growth AI stock that has climbed nearly 50% this year. This article breaks do...
New IRS data released Friday tracks audit activity at the start of Trump’s second term, showing selective enforcement...
As U.S. AI export controls tighten, investors face a push-pull: tighter access could spur China’s open-source AI ecos...
Investors are watching Viking Therapeutics as its obesity drug candidate approaches key milestones. This article brea...
Two logistics giants, UPS and FedEx, are navigating a shifting world of e commerce, global trade, and pricing pressur...
A Paychex executive recently sold a small stake, raising questions about the stock's direction. This article explains...
The S&P 500 has fallen 2.5% this month, but Gabelli Multimedia Trust and Trinity Capital have held steady. Their inco...
A prominent market strategist says investors should their money in gold, proposing a 10% allocation to hedge inflatio...
FNDF's dividend stream hinges on fundamentals and foreign cash flows. This report examines the dividend safety check:...
As GBTC’s 1.50% fee persists, the cost compounds for long-horizon investors. This piece compares the drag to cheaper ...
BlackRock has long been synonymous with ETFs, but a bigger growth story is unfolding in private markets. This article...